This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, including more biotech buyout rumors and a hot new biotech start-up.

In this video, health-care analysts David Williamson and Max Macaluso discuss the new rumors that Roche is lining up $15 billion in funding to acquire orphan-disease drugmaker BioMarin. Roche is a would-be serial acquirer, often mentioned as an interested party, but consummating few deals. It balked rather than raise the price of its offer for gene sequencer Illumina. More recently it appeared Roche was interested in Alexion, maker of the blockbuster orphan drug Soliris, as well as pipeline candidate asfotase alfa.

Watch Market Checkup and find out what to make of Roche's denials, its interest in orphan drugs, and why BioMarin would be an intriguing fit for the big pharma. 

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavidMax Macaluso, Ph.D. has no position in any stocks mentioned.

The Motley Fool recommends BioMarin Pharmaceutical and Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.